nach oben

Journal of Cutaneous Medicine and Surgery

Erschienen in:

01.08.2004 | Basic/Clinical Science

Understanding the New Clinical Landscape for Psoriasis: A Comparative Review of Biologics

verfasst von: Daniel N. Sauder, Adam J. Mamelak

Erschienen in: Journal of Cutaneous Medicine and Surgery | Ausgabe 4/2004

Einloggen, um Zugang zu erhalten

Abstract

Background

Encouraging results from clinical trials suggest that biologic therapies are effective treatments for psoriasis.

Objective

The aim of our study was to evaluate the scientific evidence for the efficacy and safety of biologic drugs for psoriasis.

Methods

The studies reviewed include data on the biologies alefacept, efalizumab, etanercept, and infliximab. This article reviews all data published in the dermatology literature listed in the MEDLINE database, as well as data presented as abstracts and posters at dermatology society meetings, including the annual meetings of the American Academy of Dermatology.

Results

The majority of the studies used an improvement from baseline of 75% or more in the psoriasis area and severity index (PASI 75) as the primary measure of efficacy.

Conclusions

Overall, biologics represent an important addition to the psoriatic therapies and have a great impact on the disease course and life quality of those afflicted with psoriasis.

Koo, J. 1996Population-based epidemiologic study of psoriasis with emphasis on quality of life assessmentDermatol Clin14485496CrossRefPubMed

National Psoriasis Foundation. About psoriasis: FAQs [online article]. Available at: http://www.psoriasis.org/b500.htm; accessed July 11, 2003

CDCP. Vital and health statistics: current estimates from the National Health Interview Survey, 1996. Centers for Disease Control and Prevention/National Center for Health Statistics. 2003

Krueger, G, Koo, J, Lebwohl, M, et al. 2001The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership surveyArch Dermatol137280284PubMed

Barankin, B, DeKoven, J. 2001Psychosocial effect of common skin diseasesCan Fam48712716

Voorhees, JJ. 1996Dohi Memorial Lecture: Psoriasis—an immunological diseaseJ Dermatol23851857PubMed

Partsch, G, Steiner, G, Leeb, BF, et al. 1997Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluidJ Rheumatol; 24518523

Danning, CL, Illei, GG, Hitchon, C, et al. 2000Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritisArthritis Rheum4312441256CrossRefPubMed

Greaves, MW, Weinstein, GD. 1995Treatment of psoriasisN Engl J Med332581588CrossRefPubMed

10.

Camisa, C. 2000Psoriasis: a clinical update on diagnosis and new therapiesCleve Clin J Med67105113, 117PubMed

11.

Guenther, L. 2000Tazarotene combination treatments in psoriasisJ Am Acad Dermatol43S36S42CrossRefPubMed

12.

Gordon, PM, Diffey, BL, Matthews, JN, Fair, PM. 1999A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasisJ Am Acad Dermatol41728732PubMed

13.

Behrens, S, Grundmann–Kollmann, M, Schiener, R, et al. 2000Combination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gelJ Am Acad Dermatol42493495CrossRefPubMed

14.

Witman, PM. 2001Topical therapies for localized psoriasisMayo Clin Proc76943949PubMed

15.

National Psoriasis Foundation. Benchmark survey on psoriasis and psoriatic arthritis. Available at: http://www.psoriasis.org/news/news/2001/200104_npfsurvey.php; accessed August 9, 2003

16.

Tutrone, WD, Kagen, MH, Barbagallo, J, et al. 2001Biologic therapy for psoriasis: a brief history, IICutis68367372PubMed

17.

LaDuca, JR, Gaspari, AA. 2001Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseasesDermatol Clin19617635CrossRefPubMed

18.

Food and Drug Administration. FDA approves first biologic therapy for psoriasis. Available at http://www.fda.gov/bbs/topics/ANSWERS/2003/ANS01194.html; accessed on November 5, 2003. FDA Talk Paper, 1-31-0003

19.

Alefacept2003(Amevive) for treatment of psoriasisMed Lett Drugs Ther453132

20.

Ortonne, JP. 2003Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasisJ Eur Acad Dermatol Verereol171216CrossRef

21.

Lebwohl, M, Christophers, E, Langley, R, et al. 2003An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasisArch Dermatol139719727CrossRefPubMed

22.

Krueger, GG, Papp, KA, Stough, DB, et al. 2002A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasisJ Am Acad Dermatol47821833CrossRefPubMed

23.

Marzella L, Papadopoulos E, Wang C. PDA Final Clinical Review: Biologic License Application STN BL 125036/0 for alefacept for treatment of moderate to sever chronic plaque psoriasis, submitted April 29, 2002

24.

Gottlieb AB, Blacker K, Duvic M, et al. Efficacy and safety of efalizumab long term treatment: preliminary findings from an open label trial [abstract]. Presented at the 61st Annual Spring 2003 Meeting of the American Academy of Dermatology, 21–26 March 2003, San Francisco, California, poster 11

25.

Gottlieb AB, Gordon KB, Koo JY, et al. Long-term efalizumab treatment maintains clinical benefit in patients with moderate to severe plaque psoriasis: updated findings from an open-label trial [abstract]. Presented at the Annual Meeting of the American Academy of Dermatology, 25–29 July 2003, Chicago, Illinois, poster 43

26.

Singri, P, West, DP, Gordon, KB. 2002Biologic therapy for psoriasis: the new therapeutic frontierArch Dermatol138657663CrossRefPubMed

27.

PDA Advisory Committee. Genentech/Xoma Raptiva potential use as second-line psoriasis therapy to be discussed by committee [press release], September 8, 2003

28.

Papadopoulos E, Marzella L. FDA Briefing Document: Biologic License Application STN BL 125075/0 for efalizumab for the treatment of moderate to severe chronic plaque psoriasis, submitted December 27, 2002

29.

Gordon KB, Tyring SK, Hamilton TK, et al. Examining duration of response and rebound during treatment with efalizumab (anti-CD 11a) [abstract]. Presented at the 61st Annual Spring 2003 Meeting of the American Academy of Dermatology, 21–26 March 2003, San Francisco, California, poster 594

30.

Mease, PJ, Goffe, BS, Metz, J, et al. 2000Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trialLancet356385390PubMed

31.

Gottlieb AB, Lowe NJ, Matheson RT, et al. Efficacy of etanercept in patients with psoriasis [abstract]. Presented at the 60th Annual Spring 2003 Meeting of the American Academy of Dermatology, 22–27 February 2002, New Orleans, Louisiana

32.

Papp K, Zitnik R. Efficacy and safety of etanercept in patients with psoriasis: results of a global 12 week phase III study [abstract]. Workshop presented at the 9th International Psoriasis Symposium, 17–22 June 2003, New York, New York

33.

Leonardi C, Gottlieb AB, Zitnik R, for the Etanercept Psoriasis Study Group. Efficacy and safety of etanercept in patients with psoriasis: results of a phase 3 study [abstract]. Presented at the International Investigative Dermatology Annual Meetings, 30 April–4 May 2003, Miami Beach, Florida, poster 0409

34.

Leonardi, CL, Powere, JL, Matheson, RT, et al. 2003Etanercept as monotherapy in patients with psoriasisN Engl J Med34920142022CrossRefPubMed

35.

Chaudhari, U, Romano, P, Mulcahy, LD, et al. 2001Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trialLancet35718421847CrossRefPubMed

36.

Gottlieb AB, Li S, Evans R, et al. Infliximab in the treatment of psoriasis: results from the first 10 weeks of the phase II trial [abstract]. Presented at the 61st Annual Spring 2003 Meeting of the American Academy of Dermatology, 21–26 March 2003, San Francisco, California, poster 596

37.

Gottlieb AB, Evans R, Li S, et al. The efficacy and safety of infliximab induction therapy in patients with moderate to svere plaque-type psoriasis [abstract]. Poster presented at the 9th International Psoriasis Symposium, 17–22 June 2003, New York, New York

Titel: Understanding the New Clinical Landscape for Psoriasis: A Comparative Review of Biologics
verfasst von: Daniel N. Sauder
Adam J. Mamelak
Publikationsdatum: 01.08.2004
Verlag: Springer-Verlag
Erschienen in: Journal of Cutaneous Medicine and Surgery / Ausgabe 4/2004
Print ISSN: 1203-4754
Elektronische ISSN: 1615-7109
DOI: https://doi.org/10.1007/s10227-003-0116-y

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Bildnachweise

Die Leitlinien für Ärztinnen und Ärzte, Nahaufnahme Rosazea auf der Wange/© Alessandro Grandini / stock.adobe.com (Symbolbild mit Fotomodell), Eine Tätowierung wird mit roter Farbe ausgefüllt/© nagaets / stock.adobe.com (Symbolbild mit Fotomodell), Operation/© Peakstock / Stock.adobe.com (Symbolbild mit Fotomodellen), Rechte Aa. carotis interna mit Wandverdickung bei Riesenzellarteriitis/© Kisyova H et al. | all rights reserved Springer Medizin Verlag GmbH

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2004

7. Surgery and Laser

Prednicarbate (Dermatop®): Profile of a Corticosteroid

4. Bullous/Mucous Membrane

1. Medical Practice

6. Phototherapy, photomedicine, and pigmentary disorder